The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Prevalence of chronic obstructive pulmonary disease (COPD) and the disease's burden varies significantly by state.

### Philosophy of the guideline ### Assessing patients Figure 1 Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. ABG, arterial blood gas; COPD, chronic obstructive pulmonary ...

An inhaler is a method of administering medication for COPD. You only need to breathe into the L-shaped gadget for it to transport the drug to your lungs. Separate inhalers may be used for each ...

Writing all this information down and using a COPD Action Plan, or keeping a journal is a great way to stay organized and reduce stress, especially in an emergency situation. Your notes should include ...

Inhaled medications are central to COPD management, but their efficacy depends on the patient's ability to generate sufficient inspiratory flow to properly inhale the medication. In this real-world ...

Emergency departments (ED s) in the U.S. have seen a surge in patient visits for mental health conditions over the past decade.And frequently these visits include episodes of patient agitation, or ...

“The Trump Administration would rather women die in emergency rooms than receive life-saving abortions,” Nancy Northup, president and CEO of the Center for Reproductive Rights, said in a ...

The Trump administration announced on Tuesday it is rescinding Biden-era guidance that uses a federal law to require hospitals to stabilize patients in need of emergency care -- including by ...

LANSING, Mich. (WLNS) — Michigan Governor Gretchen Whitmer has declared a state of emergency for the city of Lansing and Allegan and Baraga counties in the wake of a massive storm system that ...

The FDA just gave the green light to Nucala (mepolizumab), a new medication that is now an official “add-on” treatment for adults battling chronic obstructive pulmonary disease (COPD) that just isn’t ...

Synopsis: Participants had COPD, were at least 40 years old, and were new users of single-inhaler triple therapy. The main outcomes were first moderate or severe COPD exacerbation (effectiveness) and ...